학술논문
Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center.
Document Type
Letter
Author
Source
Subject
*NON-Hodgkin's lymphoma
*DIFFUSE large B-cell lymphomas
*MANTLE cell lymphoma
*CELLULAR therapy
*
*
*
Language
ISSN
1042-8194
Abstract
Whereas 38 patients (67.8% of the patients who did not receive CAR-T cells) were excluded at first (remote) evaluation, 10 (17.9%) and eight (14%) patients dropped out after first visit and after leukapheresis, respectively. Chimeric antigen receptor T-cells (CAR-T) have recently emerged as an active therapy for patients with relapse or refractory diffuse large B-cell lymphoma (R/R DLBCL) [[1]]. Among the evaluated patients, age was the only factor associated with not finally receiving the therapy, presumably because elderly patients have more comorbidities and less treatment options during the bridging period. [Extracted from the article]